Papp KA, et al. - This trial was conducted to draw a comparison between the outcomes with guselkumab, placebo, and adalimumab in patients with moderate-to-severe psoriasis utilizing the novel, validated Psoriasis Symptoms and Signs Diary (PSSD). Based on PSSD scores, results demonstrated greater improvements in symptoms and signs of psoriasis in the subjects treated with guselkumab vs placebo at week 16 or adalimumab through 48 weeks.